Latigo Biotherapeutics, Inc. Common Stock (NASDAQ:LTGO) — Market Cap & Net Worth
Market Cap & Net Worth: Latigo Biotherapeutics, Inc. Common Stock (LTGO)
Latigo Biotherapeutics, Inc. Common Stock (NASDAQ:LTGO) has a market capitalization of $1.10 Billion ($1.10 Billion) as of August 24, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #8543 globally and #2474 in its home market, demonstrating a 11.52% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Latigo Biotherapeutics, Inc. Common Stock's stock price $22.37 by its total outstanding shares 60153191 (60.15 Million). Check LTGO live share price for real-time trading data and today's change.
Latigo Biotherapeutics, Inc. Common Stock Market Cap History: 2026 to 2026
Latigo Biotherapeutics, Inc. Common Stock's market capitalization history from 2026 to 2026. Data shows growth from $1.35 Billion to $1.35 Billion (0.00% CAGR).
Latigo Biotherapeutics, Inc. Common Stock Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Latigo Biotherapeutics, Inc. Common Stock's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Check Latigo Biotherapeutics, Inc. Common Stoc (LTGO) net assets to evaluate the company's book value and shareholders' equity.
Latest Price to Sales (P/S) Ratio
No P/S ratio data available
Latest Price to Earnings (P/E) Ratio
No P/E ratio data available
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| No financial ratio data available | |||||
Competitor Companies of LTGO by Market Capitalization
Companies near Latigo Biotherapeutics, Inc. Common Stock in the global market cap rankings as of August 24, 2026. Also see LTGO cash flow metrics for how efficiently the company converts equity into cash flow.
Key companies related to Latigo Biotherapeutics, Inc. Common Stock by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #188 globally with a market cap of $130.90 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #323 globally with a market cap of $83.19 Billion USD.
- CSL Ltd (AU:CSL): Ranked #475 globally with a market cap of $57.77 Billion USD ( AU$81.65 Billion AUD).
- Samsung Biologics Co Ltd (KO:207940): Ranked #564 globally with a market cap of $48.66 Billion USD ( ₩71.80 Trillion KRW).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #188 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.90 Billion | $548.05 |
| #323 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $83.19 Billion | $834.04 |
| #475 | CSL Ltd | AU:CSL | $57.77 Billion | AU$168.30 |
| #564 | Samsung Biologics Co Ltd | KO:207940 | $48.66 Billion | ₩1551000.00 |
Latigo Biotherapeutics, Inc. Common Stock Historical Marketcap From 2026 to 2026
Between 2026 and today, Latigo Biotherapeutics, Inc. Common Stock's market cap moved from $1.35 Billion to $ 1.35 Billion, with a yearly change of 0.00%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $1.35 Billion | -- |
End of Day Market Cap According to Different Sources
On Aug 24th, 2026 the market cap of Latigo Biotherapeutics, Inc. Common Stock was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $1.10 Billion USD |
| MoneyControl | $1.10 Billion USD |
| MarketWatch | $1.10 Billion USD |
| marketcap.company | $1.10 Billion USD |
| Reuters | $1.10 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Latigo Biotherapeutics, Inc. Common Stock
Latigo Biotherapeutics, Inc. develops non-opioid pain medicines designed to stop the transmission of pain without the risk of addiction. The company's pipeline includes LTG-001, an oral NaV1.8 inhibitor designed to provide fast-acting, opioid-sparing relief for the treatment of acute pain; LTG-321, a NaV1.8 inhibitor candidate developed for the treatment of chronic musculoskeletal pain, starting … Read more